Search

Search Constraints

You searched for: Subject 616.994

Search Results

50201. Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity. (4th March 2017)

50202. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). (September 2016)

50204. Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor. (1st February 2017)

50207. Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer. (3rd August 2017)

50208. Zoledronic Acid Treatment in Primary Bone Marrow Edema Syndrome. (2nd January 2017)